Page 180 - 2019_03-Haematologica-web

586
N. Giménez et al.
References
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
2. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16(3):145– 162.
3. Delgado J, Salaverria I, Baumann T, et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica. 2014;99 (11):e231-234.
4. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lympho- cytic leukemia. J Clin Oncol. 2010;28(29): 4473–4479.
5. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8): 1403–1412.
6. Baliakas P, Hadzidimitriou A, Sutton L-A, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329–336.
7. Puente XS, Beà S, Valdés-Mas R, et al. Non- coding recurrent mutations in chronic lym- phocytic leukaemia. Nature. 2015;526 (7574):519–524.
8. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47–52.
9. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolu- tion in progression and relapse. Nature. 2015;526(7574):525–530.
10. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lym- phocytic leukemia. N Engl J Med. 2011;365(26):2497–2506.
11. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal muta- tions in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726.
12. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patient. Leukemia. 2014;28(1):108–117.
13. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122–2130.
14. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281–298.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human can- cer. Nature. 2002;417(6892):949–954.
16. Forbes SA, Beare D, Boutselakis H, et al. COSMIC: Somatic cancer genetics at high- resolution. Nucleic Acids Res. 2017;45(D1): D777–D783.
17. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–2315.
18. Tiacci E, Pettirossi V, Schiavoni G, Falini B.
Genomics of Hairy cell leukemia. J Clin
Oncol. 2017;35(9):1002–1010.
19. Pakneshan S, Salajegheh A, Smith RA, Lam
AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–356.
20. Buscà R, Pouysségur J, Lenormand P. ERK1 and ERK2 map kinases: specific roles or functional redundancy? Front Cell Dev Biol. 2016;453.
21. Jebaraj BMC, Kienle D, Bühler A, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(6):1177–1182.
prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8–10.
35. Brown NA, Furtado L V, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655– 1658.
36. Schmidt J, Ramis-Zaldivar JE, Nadeu F, et al. Mutations of MAP2K1 are frequent in pedi- atric-type follicular lymphoma and result in ERK pathway activation. Blood. 2017;130(3):323–327.
37. Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and tran- scriptional regulation. Gene. 2013;513(1):1–
22. Pandzic T, Larsson J, He L, et al. Transposon mutagenesis reveals fludarabine-resistance mechanisms in chronic lymphocytic
leukemia. Clin Cancer Res. 2016;22(24): 13.
6217–6227.
23. Damm F, Mylonas E, Cosson A, et al.
Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9):1088–1101.
24. Leeksma AC, Taylor J, Wu B, et al. Clonal diversity predicts adverse outcome in chron- ic lymphocytic leukemia. Leukemia. 2018 Jul 23. [Epub ahead of print]
25. Müller-Hermelink H, Montserrat E, Catovsky D et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: International Agency for Research on Cancer; Lyon, 2008; 4th edition. Pages 180- 183.
26. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independ- ent of del17p13: Implications for overall sur- vival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995–1004.
27. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with flu- darabine chemorefractoriness in TP53 wild- type chronic lymphocytic leukemia. Blood. 2012;119(12):2854–2862.
28. Lazarian G, Guièze R, Wu CJ. Clinical Implications of novel genomic discoveries in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(9):984–993.
29. Downward J. Targeting RAS signalling path- ways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22.
30. Imperial R, Toor OM, Hussain A, Subramanian J, Masood A. Comprehensive pancancer genomic analysis reveals (RTK)- RAS-RAF-MEK as a key dysregulated path- way in cancer: its clinical implications. Semin Cancer Biol. 2017 Nov 22. [Epub ahead of print].
31. Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
32. Sellar RS, Fend F, Akarca AU, et al. BRAFV600E mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. Br J Haematol. 2015;170(2):282–285.
33. Nadeu F, Clot G, Delgado J, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lympho- cytic leukemia. Leukemia. 2017;32(3):645- 653.
34. Waterfall JJ, Arons E, Walker RL, et al. High
38. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profil- ing in human cancer. Nat Genet. 2007;39(3):347–351.
39. Warden DW, Ondrejka S, Lin J, Durkin L, Bodo J, Hsi ED. Phospho-ERK(THR202/ Tyr214) is overexpressed in hairy cell leukemia and is a useful diagnostic marker in bone marrow trephine sections. Am J Surg Pathol. 2013;37(2):305–308.
40. Burotto M, Chiou VL, Lee J-M, Kohn EC. The MAPK pathway across different malig- nancies: a new perspective. Cancer. 2014;120(22):3446–3456.
41. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in ther- apy. Ther Adv Med Oncol. 2016;8(1):48–56.
42. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
43. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038– 2040.
44. Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013;161(1): 150–153.
45. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
46. Kordes M, Röring M, Heining C, et al. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016;30(4):937-946.
47. Yaktapour N, Meiss F, Mastroianni J, et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014;124(11):5074– 5084.
48. Ryan MB, Der CJ, Wang-Gillam A, Cox AD. Targeting RAS-mutant cancers: Is ERK the key? Trends Cancer. 2015;1(3):183–198.
49. Sullivan RJ, Infante JR, Janku F, et al. First-in- class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-esca- lation and expansion study. Cancer Discov. 2018;8(2):184-195.
50. Dietrich S, Oleś M, Lu J, et al. Drug-pertur- bation-based stratification of blood cancer. J Clin Invest. 2018;128(1):427-445.
haematologica | 2019; 104(3)
586